🚀
Enjoy a 7-Day Free Trial Thru May 02, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Tonix Pharmaceuticals Holding Corp (NAS:TNXP)
News
Tonix Pharmaceuticals Holding Corp
NAS
:TNXP (USA) Â
$ 0.16
0 (0%)
04:00 PM EST
P/E:
At Loss
P/B:
0.09
Market Cap:
$ 15.29M
Enterprise V:
$ 152.00K
Volume:
1.00M
Avg Vol (2M):
2.81M
Warning! GuruFocus detected 3 Severe warning signs with TNXP.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
1.00M
Market Cap $:
15.29M
PE Ratio:
At Loss
Avg Vol (2M):
2.81M
Enterprise Value $:
152.00K
PB Ratio:
0.09
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Tonix Pharmaceuticals Holding Corp (NAS:TNXP) Stock News, Headlines & Updates
Tonix Pharmaceuticals Holding Corp Stock News from GuruFocus
Total 364
1
2
3
4
5
6
10
Apr 24, 2024
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
Marketwired
•
7:00am
Feb 26, 2024
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
ACCESSWIRE
•
11:00am
Feb 15, 2024
Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addiction
ACCESSWIRE
•
11:00am
Feb 12, 2024
New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval
ACCESSWIRE
•
3:00pm
Feb 09, 2024
Tonix Pharmaceuticals Holding Corp to Host KOL Webinar Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at ThinkEquity Conference Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp At The June 1st Virtual Investor Summit Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp At Investor Summit (Virtual) Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corpinterview with Dr. Seth Lederman, MD, and CEO Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at EBD Group Biotech Showcase Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at ThinkEquity Conference Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at Q2 Investor Summit Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at Noble Capital Markets Investor Conference (Virtual) Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at Biotechnology Industry Organization (BIO) CEO & Investor Conference (Virtual) - Virtual Presentation Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at Raymond James Human Health Innovation Conference (Virtual) Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at ICR Virtual Conference Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp Business Update Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at SNN Network Virtual Conference Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at SNN Planet MicroCap Showcase Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at SNN Planet MicroCap Showcase Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at Tarsier Capital Management Spring Summit Transcript
GuruFocus Research
•
12:24am
Tonix Pharmaceuticals Holding Corp at Noble Financial Emerging Growth Investor Conference Transcript
GuruFocus Research
•
12:24am
Dec 14, 2023
Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL
ACCESSWIRE
•
11:00am
Oct 25, 2023
New Hope for Long COVID Sufferers
ACCESSWIRE
•
11:00am
Oct 19, 2023
Tonix Pharmaceuticals Presents Data from its Horsepox-Based Vaccine Development Platform at the World Vaccine Congress Europe
Marketwired
•
6:00am
Oct 18, 2023
Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models
Marketwired
•
6:00am
Oct 16, 2023
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder
Marketwired
•
6:00am
Oct 12, 2023
Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference
Marketwired
•
6:00am
Oct 11, 2023
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe
Marketwired
•
6:00am
Oct 09, 2023
Tonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family Conference
Marketwired
•
6:00am
Oct 04, 2023
Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain
Marketwired
•
6:00am
Sep 29, 2023
Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering
GlobeNewswire
•
11:00pm
Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering
Marketwired
•
8:00pm
Sep 28, 2023
Tonix Pharmaceuticals Announces Proposed Public Offering
Marketwired
•
4:00pm
Sep 27, 2023
Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina's Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Dis
Marketwired
•
8:00am
Sep 21, 2023
Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023
Marketwired
•
6:00am
Sep 18, 2023
Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress
Marketwired
•
6:00am
Total 364
1
2
3
4
5
6
10
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news